Figure 1.
Figure 1. Response of patient no. 16. Hematologic response (MaR-P) of a patient who initially presented with pancytopenia (white blood cell count [WBC], 2.6 = 109/L [2600/μL]; hemoglobin [Hgb], 69 g/L [6.9 g/dL]; platelets, 15 = 109/L [15 000/μL]) and a normocellular bone marrow. He was diagnosed as RCMD. He responded to immunosuppressive treatment with antithymocyte globulin but remained thrombocytopenic (around 40 = 109/L [40 000/μL]). Two years later, when his thrombocytopenia deteriorated, he received valproic acid monotherapy and responded for 5 months. After relapse he responded again to addition of ATRA. ↓ indicates 2 units of platelets were transfused.

Response of patient no. 16. Hematologic response (MaR-P) of a patient who initially presented with pancytopenia (white blood cell count [WBC], 2.6 = 109/L [2600/μL]; hemoglobin [Hgb], 69 g/L [6.9 g/dL]; platelets, 15 = 109/L [15 000/μL]) and a normocellular bone marrow. He was diagnosed as RCMD. He responded to immunosuppressive treatment with antithymocyte globulin but remained thrombocytopenic (around 40 = 109/L [40 000/μL]). Two years later, when his thrombocytopenia deteriorated, he received valproic acid monotherapy and responded for 5 months. After relapse he responded again to addition of ATRA. ↓ indicates 2 units of platelets were transfused.

Close Modal

or Create an Account

Close Modal
Close Modal